Immunotherapy in antiphospholipid syndrome
C Lopez-Pedrera, MA Aguirre, P Ruiz-Limon… - International …, 2015 - Elsevier
C Lopez-Pedrera, MA Aguirre, P Ruiz-Limon, C Perez-Sanchez, Y Jimenez-Gomez…
International immunopharmacology, 2015•ElsevierAntiphospholipid syndrome (APS) is a disorder characterized by the association of arterial or
venous thrombosis and/or pregnancy morbidity with the presence of antiphospholipid
antibodies (anticardiolipin antibodies, lupus anticoagulant antibodies, and/or anti-β2-
glycoprotein I antibodies). Thrombosis is the major manifestation in patients with aPLs, but
the spectrum of symptoms and signs associated with aPLs has broadened considerably,
and other manifestations, such as thrombocytopenia, non-thrombotic neurological …
venous thrombosis and/or pregnancy morbidity with the presence of antiphospholipid
antibodies (anticardiolipin antibodies, lupus anticoagulant antibodies, and/or anti-β2-
glycoprotein I antibodies). Thrombosis is the major manifestation in patients with aPLs, but
the spectrum of symptoms and signs associated with aPLs has broadened considerably,
and other manifestations, such as thrombocytopenia, non-thrombotic neurological …
Abstract
Antiphospholipid syndrome (APS) is a disorder characterized by the association of arterial or venous thrombosis and/or pregnancy morbidity with the presence of antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant antibodies, and/or anti-β2-glycoprotein I antibodies).
Thrombosis is the major manifestation in patients with aPLs, but the spectrum of symptoms and signs associated with aPLs has broadened considerably, and other manifestations, such as thrombocytopenia, non-thrombotic neurological syndromes, psychiatric manifestations, livedo reticularis, skin ulcers, hemolytic anemia, pulmonary hypertension, cardiac valve abnormality, and atherosclerosis, have also been related to the presence of those antibodies.
Several studies have contributed to uncovering the basis of antiphospholipid antibody pathogenicity, including the targeted cellular components, affected systems, involved receptors, intracellular pathways used, and the effector molecules that are altered in the process.
Therapy for thrombosis traditionally has been based on long-term oral anticoagulation; however, bleeding complications and recurrence despite high-intensity anticoagulation can occur. The currently accepted first-line treatment for obstetric APS (OAPS) is low-dose aspirin plus prophylactic unfractionated or low-molecular-weight heparin (LMWH). However, in approximately 20% of OAPS cases, the final endpoint, i.e. a live birth, cannot be achieved.
Based on all the data obtained in different research studies, new potential therapeutic approaches have been proposed, including the use of new oral anticoagulants, statins, hydroxychloroquine, coenzyme Q10, B-cell depletion, platelet and TF inhibitors, peptide therapy or complement inhibition among others. Current best practice in use of these treatments is discussed.
Elsevier